Breast SurgeryVenous Thromboembolic Disease in Autogenous Breast ReconstructionPannucci, Christopher J. MD; Chang, Edwin Y. MD; Wilkins, Edwin G. MDAuthor Information From the Section of Plastic Surgery, Department of Surgery, University of Michigan, Ann Arbor, Michigan. Received January 16, 2008 and accepted for publication, after revision, July 31, 2008. Reprints: Christopher Pannucci, MD, 1500 East Medical Center Drive, 2130 Taubman Center, Box 0340, Ann Arbor, MI 48109. E-mail: firstname.lastname@example.org. Annals of Plastic Surgery: July 2009 - Volume 63 - Issue 1 - p 34-38 doi: 10.1097/SAP.0b013e318188bedf Buy Metrics Abstract Venous thromboembolic disease (VTE) is a cause of significant morbidity and mortality in patients with cancer. Large studies have estimated that VTE occurs in up to 1.1% of patients undergoing breast cancer tumor extirpation and in up to 1.5% of patients undergoing breast cancer reconstruction. This study sought to retrospectively review the experience of a large university practice with TRAM, DIEP, and latissimus flap reconstruction for mastectomy defects and evaluate our rate of VTE. In our series of 271 consecutive patients, 2 had deep venous thromboses, 2 had both deep venous thromboses and pulmonary emboli, and 2 had pulmonary embolus alone. VTE incidence was 2.2%, a relatively high rate compared with previously published, large population studies of VTE in breast reconstruction patients. Review of the literature suggests that physicians have poor compliance with established guidelines for prophylaxis and treatment of VTE in general and orthopedic surgery populations. Unfortunately, no specific guidelines are available for patients undergoing operative intervention for breast cancer or autogenous tissue based reconstruction. VTE is significantly under-diagnosed: clinical findings alone are unreliable, and the true prevalence may be greater than twice what is reported. Further research is needed in this largely unexplored field to determine appropriate means of VTE prophylaxis and treatment in the breast cancer population. © 2009 Lippincott Williams & Wilkins, Inc.